INVESTMENTS IN INNOVATION
Promentis Pharmaceuticals, Inc.
826 N. Plankinton Avenue Suite 400
Promentis Pharmaceuticals, Inc. is developing novel compounds for the treatment of central nervous system disorders. Promentis’ drug development efforts are focused on the neurotransmitter glutamate, oxidative stress, and their critical role in the pathophysiology of schizophrenia, autism and selected rare, pediatric diseases that affect the brain.